Onyx, Bayer Enjoy 'Upside Surprise' on Regorafenib
Ahead of schedule, on Wednesday Onyx Pharmaceuticals Inc. and partner Bayer HealthCare Pharmaceuticals reported positive Phase III data for the VEGF-multikinase inhibitor regorafenib (BAY 73-4506) in patients with metastatic colorectal cancer (mCRC) whose disease has progressed after standard treatment.
While keeping details under wraps, the companies said the trial met its primary endpoint of statistically significant improvement in overall survival.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter